PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance

Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in human lung cancer cells. In addition, we explor...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Minghui, Cui, Liyuan, Li, Xin, Xia, Chunqiu, Li, Yongwen, Wang, Rui, Ren, Fan, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952807/
https://www.ncbi.nlm.nih.gov/pubmed/33534964
http://dx.doi.org/10.1111/1759-7714.13866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952807/
https://www.ncbi.nlm.nih.gov/pubmed/33534964
http://dx.doi.org/10.1111/1759-7714.13866

Ejemplares similares